Trial Profile

Phase II trial of GS 6615 in patients with long QT-3 syndrome.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 08 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eleclazine (Primary)
Indications Long QT syndrome
Focus Pharmacodynamics
Sponsors Gilead Sciences

Most Recent Events

24 Jul 2014 Planned initiation date changed to 1 Dec 2014, as reported in a Gilead media release.
19 May 2014 This trial is planned to be initiated later in 2014, according to a Gilead Sciences media release.
19 May 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com